The European Medicines Agency’s new email notification feature in the Clinical Trials Information System demonstrates substantial operational impact, with automated regulatory alerts achieving 95 percent coverage of trial submissions and status changes. The system delivers real-time updates on assessments and regulatory decisions, eliminating the need for manual platform checks that previously consumed significant administrative resources for trial sponsors and investigators. Supporting data indicates that 85 percent of regulatory alerts are now automated, while 75 percent of status change notifications reach stakeholders instantaneously. This efficiency gain is particularly significant given CTIS’s consolidation of clinical trial applications from all EU member states and the European Economic Area into a single transparent repository. The notification infrastructure enables role-specific customisation, ensuring that each stakeholder—whether sponsor, principal investigator, or regulatory affairs professional—receives only relevant updates. These metrics underscore how digital infrastructure investments can substantially improve transparency and operational efficiency in clinical research governance. Read the full article on GMJ Newsroom.
Was this article helpful?
